Company Overview of G1 Therapeutics, Inc.
G1 Therapeutics, Inc. researches and develops small molecule therapies to address unmet needs in oncology. It offers programs including G1T28-1, to protect bone marrow and other organs from side effects of chemotherapy treatments and radiation. The company was formerly known as G-Zero Therapeutics Inc. G1 Therapeutics, Inc. was founded in 2008 and is based in Research Triangle Park, North Carolina.
79 T.W. Alexander Drive
4401 Research Commons
Research Triangle Park, NC 27709
Founded in 2008
Key Executives for G1 Therapeutics, Inc.
Chief Executive Officer and Director
Co-Founder and Scientific and Clinical Advisor
Compensation as of Fiscal Year 2014.
G1 Therapeutics, Inc. Key Developments
G1 Therapeutics, Inc. Initiates Phase 1 Clinical Trial of G1T28-1
Sep 10 14
G1 Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications. The randomized, placebo-controlled, single ascending dose study will assess the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers. The study is being conducted in collaboration with PRA Health Sciences and is currently enrolling subjects in the Netherlands. Data collected from the study will inform dose and schedule for further development of G1T28-1, either as a bone marrow chemoprotectant or as an antineoplastic agent.
G1 Therapeutics, Inc. Announces Executive appointments
Jun 17 14
G1 Therapeutics, Inc. announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer. Dr. Malik will oversee the advancement of the company's lead CDK 4/6 inhibitor, G1T28-1, into a Phase I study for the reduction of chemotherapy-induced myelosuppression in the third quarter of this year. Mr. Mossinghoff will assume responsibility for G1's finances and business development efforts. Dr. Malik has more than 20 years of experience in drug development focused on oncology. Most recently, he served as Chief Medical Officer and management board member at Agennix AG. Mr. Mossinghoff has more than 25 years of domestic and international pharmaceutical industry experience. He has served as president of Integrated Oncology Solutions and Inspire Pharmaceuticals.
G1 Therapeutics, Inc. Appoints Mark Velleca as Chief Executive Officer
May 20 14
G1 Therapeutics, Inc. announced the appointment of Mark Velleca, M.D., Ph.D. as chief executive officer, effective immediately. Previously, Dr. Velleca was instrumental in founding, building, and leading CGI Pharmaceuticals up through its acquisition by Gilead Sciences in 2010. He most recently served as executive vice president at The Leukemia & Lymphoma Society (LLS).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|